# Encompass Health Corp: Form 10-Q for the period ended Sep 30, 2023

- Company: [Encompass Health Corp](/companies/ehc.md) (CIK 785161)
- Form: 10-Q
- Filed: 2023-11-01
- Accepted by EDGAR: Nov 1, 2023, 15:30 ET
- Period: 2023-09-30
- Accession: 0000785161-23-000070
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/785161/000078516123000070/ehc-20230930.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/785161/000078516123000070/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2023-09-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2023-07-01 to 2023-09-30 | $1.21bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months, 2023-01-01 to 2023-09-30 | $3.55bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Interest expense | 3 months, 2023-07-01 to 2023-09-30 | $35.9m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2023-01-01 to 2023-09-30 | $108.6m | us-gaap:InterestExpense |
| Income tax | 3 months, 2023-07-01 to 2023-09-30 | $30.3m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2023-01-01 to 2023-09-30 | $95.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2023-07-01 to 2023-09-30 | $85.3m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2023-01-01 to 2023-09-30 | $264.4m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2023-07-01 to 2023-09-30 | $0.84 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2023-01-01 to 2023-09-30 | $2.62 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2023-07-01 to 2023-09-30 | $0.85 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2023-01-01 to 2023-09-30 | $2.64 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2023-07-01 to 2023-09-30 | 101,400,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2023-01-01 to 2023-09-30 | 101,100,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2023-01-01 to 2023-09-30 | $649.8m | us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations |
| Capital expenditure | 9 months, 2023-01-01 to 2023-09-30 | $360.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2023-01-01 to 2023-09-30 | $45.5m | us-gaap:PaymentsOfDividendsCommonStock |
| Cash and equivalents | at 2023-09-30 | $99.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2023-09-30 | $813.7m | us-gaap:AssetsCurrent |
| Total assets | at 2023-09-30 | $5.96bn | us-gaap:Assets |
| Current liabilities | at 2023-09-30 | $639.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2023-09-30 | $3.78bn | us-gaap:Liabilities |
| Shareholders' equity | at 2023-09-30 | $1.56bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 57,694 characters.

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) relates to Encompass Health Corporation and its subsidiaries and should be read in conjunction with our condensed consolidated financial statements included under Part I, Item 1, *Financial Statements (Unaudited)*, of this report. In addition, the following MD&A should be read in conjunction with our audited consolidated financial statements for the year ended December 31, 2022, Part II, Item 7, *Management’s Discussion and Analysis of Financial Condition and Results of Operations,* Part I, Item 1, *Business,* and Item 1A, *Risk Factors,* included in our Annual Report on Form 10-K for the year ended December 31, 2022 filed on February 27, 2023 (collectively, the “2022 Form 10‑K”).

This MD&A is designed to provide the reader with information that will assist in understanding our condensed consolidated financial statements, the changes in certain key items in those financial statements from period to period, and the primary factors that accounted for those changes, as well as how certain accounting principles affect our condensed consolidated financial statements. See “Cautionary Statement Regarding Forward-Looking Statements” on page ii of this report, which is incorporated herein by reference for a description of important factors that could cause actual results to differ from expected results. See also Item 1A, *Risk Factors*, of this report and to the 2022 Form 10‑K.

### Executive Overview

#### Our Business

We are the nation’s largest owner and operator of inpatient rehabilitation hospitals in terms of patients treated, revenues, and number of hospitals. We provide specialized rehabilitative treatment on an inpatient basis. We operate hospitals in 37 states and Puerto Rico, with concentrations in the eastern half of the United States and Texas. As of September 30, 2023, we operate 159 inpatient rehabilitation hospitals. For additional information about our business, see Item 1, *Business*, and Item 1A, *Risk Factors*, of the 2022 Form 10‑K.

#### Spin Off of Home Health and Hospice Business

On July 1, 2022, we completed the previously announced separation of our home health and hospice business through the distribution (the “Spin Off”) of all of the outstanding shares of common stock, par value $0.01 per share, of Enhabit, Inc. (“Enhabit”) to the stockholders of record of Encompass Health as of the close of business on June 24, 2022 (the “Record Date”). The Spin Off was effective at 12:01 a.m., Eastern Time, on July 1, 2022. The Spin Off was structured as a pro rata distribution of one share of Enhabit common stock for every two shares of Encompass Health common stock held of record as of the Record Date. No fractional shares were distributed. A cash payment was made in lieu of any fractional shares. As a result of the Spin Off, Enhabit is now an independent public company and its common stock is listed under the symbol “EHAB” on the New York Stock Exchange.

In accordance with applicable accounting guidance, the historical results of Enhabit have been presented as discontinued operations and, as such, have been excluded from continuing operations for all periods presented. Our presentation of discontinued operations excludes any allocation of general corporate and overhead costs as well as interest expense. Prior to July 1, 2022, we operated under two reporting segments. We now operate under a single reporting segment. For additional information see Note 2, *Spin Off of Home Health and Hospice Business*, to the condensed consolidated financial statements included in Part I, Item 1, *Financial Statements (Unaudited)*, of this report.

In connection with the Spin Off, on June 30, 2022, we entered into several agreements with Enhabit that govern the relationship of the parties following the Spin Off, including a Separation and Distribution Agreement, a Transition Services Agreement, a Tax Matters Agreement and an Employee Matters Agreement. See also Note 2, *Spin Off of Home Health and Hospice Business,* to the condensed consolidated financial statements included in Part I, Item 1, *Financial Statements (Unaudited)*, of this report.

#### 2023 Overview

During the three and nine months ended September 30, 2023, *Net operating revenues* increased 10.8% and 10.7%, respectively, over the same periods of 2022 due primarily to volume growth. See “Results of Operations” section of this Item for additional volume information.

In our continued development and expansion efforts during 2023, we:

- began operating our new 51-bed inpatient rehabilitation hospital and 22-bed hospital-in-hospital satellite in Knoxville, Tennessee with our joint venture partner Covenant Health in March 2023;
- began operating our new 36-bed inpatient rehabilitation hospital in Eau Claire, Wisconsin with our joint venture partner Hospital Sisters Health System in March 2023;
- began operating our new 40-bed inpatient rehabilitation hospital in Owasso, Oklahoma with our joint venture partner Ascension St. John in March 2023;
- began operating our new 50-bed inpatient rehabilitation hospital in Clermont, Florida in April 2023;
- began operating our new 60-bed inpatient rehabilitation hospital in Bowie, Maryland in June 2023 (joint venture partnership with University of Maryland Rehabilitation Institute of Southern Maryland, LLC began in July 2023);
- began operating our new 40-bed inpatient rehabilitation hospital in Columbus, Georgia with our joint venture partner Piedmont Healthcare, Inc. in September 2023;
- continued our capacity expansions by adding 41 new beds to existing hospitals; and
- announced or continued the development of the following hospitals:

|  | Number of New Beds 2023 | 2024(2) | 2025(2) | 2026(2) |
| --- | ---: | ---: | ---: | ---: |
| Prosper, Texas | 40 | — | — | — |
| Fitchburg, Wisconsin | 56 | — | — | — |
| Kissimmee, Florida | — | 50 | — | — |
| Atlanta, Georgia(1) | — | 40 | — | — |
| Johnston, Rhode Island | — | 50 | — | — |
| Fort Mill, South Carolina | — | 39 | — | — |
| Louisville, Kentucky(1) | — | 40 | — | — |
| Houston, Texas | — | 61 | — | — |
| Daytona Beach, Florida | — | — | 50 | — |
| Fort Myers, Florida(1) | — | — | 60 | — |
| Lake Worth, Florida | — | — | 50 | — |
| Concordville, Pennsylvania | — | — | 50 | — |
| Norristown, Pennsylvania | — | — | 50 | — |
| Wildwood, Florida | — | — | 50 | — |
| Athens, Georgia(1) | — | — | 40 | — |
| St. Petersburg, Florida | — | — | 50 | — |
| Palm Beach Gardens, Florida | — | — | — | 50 |
| Amarillo, Texas | — | — | — | 50 |
| Strongsville, Ohio | — | — | — | 40 |
| Danbury, Connecticut | — | — | — | 40 |

(1) Expected joint venture

(2) Opening dates are tentative

We also continued our shareholder distributions. In October 2022, February 2023, May 2023, and July 2023, our board of directors declared cash dividends of $0.15 per share that were paid in January 2023, April 2023, July 2023, and October 2023, respectively. On October 19, 2023, our board of directors declared a cash dividend of $0.15 per share, payable on January 16, 2024 to stockholders of record on January 2, 2024. For additional information see the “Liquidity and Capital Resources” section of this Item.

#### Business Outlook

We remain highly optimistic regarding the intermediate and long-term prospects of our business. Demographic trends, such as population aging, should continue to increase long-term demand for the services we provide. While we treat patients of all ages, most of our patients are 65 and older, and the number of Medicare enrollees is expected to grow approximately 3% per year for the foreseeable future, reaching approximately 73 million people over the age of 65 by 2030. More specifically, the average age of our Medicare patients is approximately 76, and the population group ranging in ages from 75 to 79 is expected to grow at approximately 5% per year through 2026. We believe the demand for the services we provide will continue to increase as the U.S. population ages. We believe these factors align with our strengths in, and focus on, inpatient rehabilitation services.

We are committed to delivering high-quality, cost-effective patient care. As the nation’s largest owner and operator of inpatient rehabilitation hospitals in terms of patients treated, revenues, and number of hospitals, we believe we differentiate ourselves from our competitors based on, among other things, the quality of our clinical outcomes, our cost-effectiveness, our financial strength, and our extensive application of technology. We also believe our competitive strengths discussed in Item 1, *Business, “*Competitive Strengths,” of the 2022 Form 10-K, give us the ability to adapt and succeed in a healthcare industry facing regulatory uncertainty around attempts to improve outcomes and reduce costs.

The healthcare industry faces the prospect of ongoing efforts to transform the healthcare system to coordinated care delivery and payment models. The nature, timing and extent of that transformation remains uncertain, as the development and implementation of new care delivery and payment systems will require significant time and resources. Our goal is to position the Company in a prudent manner to be responsive to industry shifts. We have invested in our core business and created an infrastructure that enables us to provide high-quality care on a cost-effective basis. We have been disciplined in creating a capital structure that is flexible with no significant debt maturities prior to 2025. We continue to have a strong, well-capitalized balance sheet, including a substantial portfolio of owned real estate, and ample availability under our revolving credit facility, which along with the cash flows generated from operations should, we believe, provide sufficient support for our ability to adapt to changes in reimbursement, sustain our business model, and grow through de novo and bed additions. See also Item 1, *Business, “*Competitive Strengths” and “Strategy and 2023 Strategic Priorities” of the 2022 Form 10‑K.

#### Key Challenges

Healthcare is a highly regulated industry facing many well-publicized regulatory and reimbursement challenges. Medicare reimbursement for inpatient rehabilitation facilities (“IRFs”) has recently undergone significant changes. The future of many aspects of healthcare regulation generally and Medicare reimbursement specifically remains uncertain. Successful healthcare providers are those able to adapt to changes in the regulatory and operating environments, build strategic relationships across the healthcare continuum, and consistently provide high-quality, cost-effective care. We believe we have the necessary capabilities—change agility, strategic relationships, quality of patient outcomes, cost effectiveness, and ability to capitalize on growth opportunities—to adapt to and succeed in a dynamic, highly regulated industry, and we have a proven track record of doing so. For a detailed discussion of the challenges we face, see Item 7, *Management’s Discussion and Analysis of Financial Condition and Results of Operations, “*Executive Overview—Key Challenges” of the 2022 Form 10‑K.

As we continue to execute our business plan, the following are some of the key challenges we face.

- Operating in a Highly Regulated Industry. We are required to comply with extensive and complex laws and regulations at the federal, state, and local government levels. More specifically, because Medicare comprises a significant portion of our *Net operating revenues*, failure to comply with the laws and regulations governing the Medicare program and related matters, including anti-kickback and anti-fraud requirements, could materially and adversely affect us. These rules and regulations have affected, or could in the future affect, our business activities by having an impact on the reimbursement we receive for services provided or the costs of compliance, mandating new documentation standards, requiring additional licensure or certification, regulating our relationships with physicians and other referral sources, regulating the use of our properties, and limiting our ability to enter new markets or add new capacity to existing hospitals. Ensuring continuous compliance with extensive laws and regulations is an operating requirement for all healthcare providers. See Item 1, *Business, “*Regulation,” Item 1A, *Risk Factors, “*Reimbursement Risks” and “Other Regulatory Risks” of the 2022 Form 10‑K for detailed discussions of the most important regulations we face and our programs intended to ensure we comply with those regulations.

Reimbursement claims made by healthcare providers, including inpatient rehabilitation hospitals, are subject to audit from time to time by governmental payors, such as Centers for Medicare & Medicaid Services (“CMS”) and state Medicaid programs, their agents, such as the Medicare Administrative Contractors that act as fiscal intermediaries for all Medicare billings, other auditors contracted by CMS, and private insurance carriers, as well as the United States Department of Health and Human Services Office of Inspector General. These audits as well as the ordinary course claim reviews of our billings result in payment denials, including recoupment of previously paid claims from current accounts receivable. Healthcare providers can challenge any denials through an administrative appeals process that can be extremely lengthy, taking up to several years. During the first quarter of 2023, a Supplemental Medical Review Contractor (“SMRC”) initiated a review of claims from March 2020 through December 2020 totaling approximately $21 million. We have received initial results for the claims under review and approximately 85% of these have been approved with approximately $3 million under appeal. For additional details of our claim reviews, see Item 1, *Business, “*Sources of Revenues,” Item 1A, *Risk Factors, “*Reimbursement Risks,” and Note 1, *Summary of Significant Accounting Policies, “*Net Operating Revenues” and “Accounts Receivable,” of the 2022 Form 10-K.

- Changes in Medicare Reimbursement and Regulatory Requirements for Operating IRFs. On July 27, 2023, CMS released its notice of final rulemaking for fiscal year 2024 for IRFs (the “2024 Final Rule”) under the inpatient rehabilitation facility prospective payment system. The 2024 Final Rule will implement a net 3.4% market basket increase (market basket update of 3.6% reduced by a productivity adjustment of 0.2%) effective for discharges between October 1, 2023 and September 30, 2024. The 2024 Final Rule also includes changes that impact our hospital-by-hospital base rate for Medicare reimbursement. Such changes include, but are not limited to, revisions to the wage index, updates to outlier payments, updates to the case-mix group relative weights and average lengths of stay values, and modifications of the IRF Quality Reporting Program. Based on our analysis that utilizes, among other things, the acuity of our patients annualized over a twelve-month period ended June 30, 2023, our experience with outlier payments over this same time frame, and other factors, we believe the 2024 Final Rule will result in a net increase to our Medicare payment rates of approximately 3.3% effective October 1, 2023.

Beginning August 21, 2023, CMS implemented a five-year review choice demonstration (“RCD”) for IRF services in Alabama. CMS plans to expand RCD to Pennsylvania, Texas, and California, but the timing of this expansion is not known. We operate 46 inpatient rehabilitation hospitals (representing approximately 30% of our IRF Medicare claims) in those four states. CMS has announced it will expand RCD to include additional IRFs based on the Medicare Administrative Contractor to which those IRFs submit claims. Under RCD, participating IRFs have an initial choice between pre-claim or post-payment review of 100% of claims submitted to demonstrate compliance with applicable Medicare coverage and clinical documentation requirements. We have selected the pre-claim option for our IRFs in Alabama. Under the pre-claim review choice, services can begin prior to the submission of the review request and continue while the decision is being made. The pre-claim review request with required documentation must be submitted, reviewed, and approved before the final claim is paid. If a certain percentage of the claims reviewed are found to be valid, the IRF may then opt out of the 100% review. That percentage will initially be 80% or greater and eventually increase to 90% or greater in subsequent review cycles. In opting out, the IRF may elect spot prepayment reviews of samples consisting of 5% of total claims or selective post-payment review of a statistically valid random sample. RCD does not create new documentation requirements. Given we are in the early stages of RCD, we cannot predict the impact, if any, it may have on the collectability of our Medicare claims over its five-year term and ultimately our financial position, results of operations, and cash flows.

- Maintaining Strong Volume Growth. Various factors, including competition and increasing regulatory and administrative burdens, may impact our ability to maintain and grow our hospital volumes. In any particular market, we may encounter competition from local or national entities with longer operating histories or other competitive advantages, such as acute-care hospitals who provide post-acute services similar to ours or other post-acute providers with relationships with referring acute-care hospitals or physicians. Aggressive payment review practices by Medicare contractors, aggressive enforcement of regulatory policies by government agencies, and restrictive or burdensome rules, regulations or statutes governing admissions practices may lead us to not accept patients who would be appropriate for and would benefit from the services we provide. In addition, from time to time, we must get regulatory approval to expand our services and locations in states with certificate of need laws. This approval may be withheld or take longer than expected. In the case of new-store volume growth, the addition of hospitals to our portfolio also may be difficult and take longer than expected.
- Recruiting and Retaining High-Quality Personnel. Recruiting and retaining qualified personnel, including management, for our inpatient hospitals remain a high priority for us. We attempt to maintain a comprehensive compensation and benefits package that allows us to remain competitive in this challenging staffing environment while remaining consistent with our goal of being a high-quality, cost-effective provider of post-acute services. Additionally, our operations have been affected and may in the future be affected by staffing shortages where competition creates a nursing shortage in a given market. In recent years, staffing shortages have resulted in increased labor costs, including significant sign-on and shift bonuses, and increased use of contract labor. See Item 1A, *Risk Factors*, of the 2022 Form 10‑K for further discussion of competition for staffing, shortages of qualified personnel, and other factors that may increase our labor costs and constrain our ability to take new patients.

We remain confident in the prospects of our business based on the increasing demands for the services we provide to an aging population. This confidence is further supported by our strong financial foundation and the substantial investments we have made in our business. We have a proven track record of working through difficult situations, and we believe in our ability to overcome current and future challenges.

### Results of Operations

#### Payor Mix

We derived consolidated *Net operating revenues* from the following payor sources:

|  | Three Months Ended September 30, 2023 | 2022 | Nine Months Ended September 30, 2023 | 2022 |
| --- | ---: | ---: | ---: | ---: |
| Medicare | 65.2% | 65.3% | 64.8% | 65.0% |
| Medicare Advantage | 15.9% | 15.0% | 16.2% | 15.0% |
| Managed care | 11.2% | 11.6% | 11.2% | 11.9% |
| Medicaid | 4.1% | 4.4% | 4.1% | 4.3% |
| Other third-party payors | 0.9% | 0.9% | 0.9% | 0.9% |
| Workers’ compensation | 0.5% | 0.6% | 0.6% | 0.6% |
| Patients | 0.3% | 0.3% | 0.3% | 0.4% |
| Other income | 1.9% | 1.9% | 1.9% | 1.9% |
| Total | 100.0% | 100.0% | 100.0% | 100.0% |

For additional information regarding our payors, see the “Sources of Revenues” section of Item 1, *Business*, of the 2022 Form 10‑K.

#### Our Results

Our consolidated results of operations were as follows:

*(In Millions, Except Percentage Change)*

|  | Three Months Ended September 30, 2023 | 2022 | Percentage Change 2023 vs. 2022 | Nine Months Ended September 30, 2023 | 2022 | Percentage Change 2023 vs. 2022 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Net operating revenues | $1,206.9 | $1,089.5 | 10.8% | $3,554.4 | $3,211.3 | 10.7% |
| Operating expenses: |  |  |  |  |  |  |
| Salaries and benefits | 658.6 | 605.6 | 8.8% | 1,923.8 | 1,778.9 | 8.1% |
| Other operating expenses | 183.7 | 172.0 | 6.8% | 534.3 | 500.3 | 6.8% |
| Occupancy costs | 14.2 | 12.4 | 14.5% | 42.3 | 41.6 | 1.7% |
| Supplies | 53.9 | 51.1 | 5.5% | 159.7 | 148.2 | 7.8% |
| General and administrative expenses | 49.8 | 37.9 | 31.4% | 148.6 | 111.5 | 33.3% |
| Depreciation and amortization | 67.3 | 62.1 | 8.4% | 203.8 | 180.3 | 13.0% |
| Total operating expenses | 1,027.5 | 941.1 | 9.2% | 3,012.5 | 2,760.8 | 9.1% |
| Loss on early extinguishment of debt | — | — | —% | — | 1.4 | (100.0)% |
| Interest expense and amortization of debt discounts and fees | 35.9 | 38.2 | (6.0)% | 108.6 | 138.2 | (21.4)% |
| Other (income) expense | (0.5) | 3.6 | (113.9)% | (6.8) | 13.6 | (150.0)% |
| Equity in net income of nonconsolidated affiliates | (1.0) | (0.7) | 42.9% | (2.3) | (2.6) | (11.5)% |
| Income from continuing operations before income tax expense | 145.0 | 107.3 | 35.1% | 442.4 | 299.9 | 47.5% |
| Provision for income tax expense | 30.3 | 21.8 | 39.0% | 95.0 | 68.2 | 39.3% |
| Income from continuing operations | 114.7 | 85.5 | 34.2% | 347.4 | 231.7 | 49.9% |
| (Loss) income from discontinued operations, net of tax | (1.3) | (18.5) | (93.0)% | (3.5) | 16.7 | (121.0)% |
| **Net income** | 113.4 | 67.0 | 69.3% | 343.9 | 248.4 | 38.4% |
| Less: Net income attributable to noncontrolling interests included in continuing operations | (28.1) | (21.6) | 30.1% | (79.5) | (65.5) | 21.4% |
| Less: Net income attributable to noncontrolling interests included in discontinued operations | — | — | —% | — | (1.3) | (100.0)% |
| Less: Net and comprehensive income attributable to noncontrolling interests | (28.1) | (21.6) | 30.1% | (79.5) | (66.8) | 19.0% |
| **Net income attributable to Encompass Health** | $85.3 | $45.4 | 87.9% | $264.4 | $181.6 | 45.6% |

23

### Operating Expenses as a % of Net Operating Revenues

| Operating expenses: | Three Months Ended September 30, 2023 | 2022 | Nine Months Ended September 30, 2023 | 2022 |
| --- | ---: | ---: | ---: | ---: |
| Salaries and benefits | 54.6% | 55.6% | 54.1% | 55.4% |
| Other operating expenses | 15.2% | 15.8% | 15.0% | 15.6% |
| Occupancy costs | 1.2% | 1.1% | 1.2% | 1.3% |
| Supplies | 4.5% | 4.7% | 4.5% | 4.6% |
| General and administrative expenses | 4.1% | 3.5% | 4.2% | 3.5% |
| Depreciation and amortization | 5.6% | 5.7% | 5.7% | 5.6% |
| Total operating expenses | 85.1% | 86.4% | 84.8% | 86.0% |

Additional information regarding our operating results is as follows:

*(In Millions, Except Percentage Change)*

| Net operating revenues: | Three Months Ended September 30, 2023 | 2022 | Percentage Change 2023 vs. 2022 | Nine Months Ended September 30, 2023 | 2022 | Percentage Change 2023 vs. 2022 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Inpatient | $1,180.5 | $1,064.6 | 10.9% | $3,477.0 | $3,138.6 | 10.8% |
| Outpatient and other | 26.4 | 24.9 | 6.0% | 77.4 | 72.7 | 6.5% |
| **Net operating revenues** | $1,206.9 | $1,089.5 | 10.8% | $3,554.4 | $3,211.3 | 10.7% |
|  | **(Actual Amounts)** |  |  |  |  |  |
| Discharges | 57,665 | 53,743 | 7.3% | 170,233 | 156,416 | 8.8% |
| Net patient revenue per discharge | $20,472 | $19,809 | 3.3% | $20,425 | $20,066 | 1.8% |
| Outpatient visits | 28,604 | 34,348 | (16.7)% | 91,208 | 105,506 | (13.6)% |
| Average length of stay (days) | 12.4 | 12.7 | (2.4)% | 12.4 | 12.8 | (3.1)% |
| Occupancy % | 72.8 % | 71.4 % | 2.0% | 72.3 % | 70.6 % | 2.4% |
| # of licensed beds | 10,677 | 10,356 | 3.1% | 10,677 | 10,356 | 3.1% |
| Occupied beds | 7,773 | 7,394 | 5.1% | 7,719 | 7,311 | 5.6% |
| Full-time equivalents\* | 26,500 | 25,061 | 5.7% | 26,003 | 24,454 | 6.3% |
| Employees per occupied bed | 3.41 | 3.39 | 0.6% | 3.37 | 3.34 | 0.9% |

\* Full-time equivalents included in the above table represent our employees who participate in or support the operations of our hospitals and include full-time equivalents related to contract labor.

We actively manage the productive portion of our *Salaries and benefits* utilizing certain metrics, including employees per occupied bed, or “EPOB.” This metric is determined by dividing the number of full-time equivalents, including full-time equivalents from the utilization of contract labor, by the number of occupied beds during each period.

In the discussion that follows, we use “same-store” comparisons to explain the changes in certain performance metrics and line items within our financial statements. We calculate same-store comparisons based on hospitals open throughout both the full current periods and prior periods presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on our results of operations.

#### Net Operating Revenues

Our consolidated *Net operating revenues* increased during the three months ended September 30, 2023 compared to the same period of 2022 primarily due to increased volumes. Discharge growth included a 4.3% increase in same-store discharges. Discharge growth from new stores during the three months ended September 30, 2023 compared to the same period of 2022 resulted from our joint ventures in Moline, Illinois (August 2022), Grand Forks, North Dakota (August 2022), Naples, Florida (September 2022), Eau Claire, Wisconsin (March 2023), Knoxville, Tennessee (March 2023), Owasso, Oklahoma (March 2023), and Bowie, Maryland (June 2023), as well as our wholly owned hospital in Clermont, Florida (April 2023). Growth in net patient revenue per discharge during the three months ended September 30, 2023 compared to the same period of 2022 primarily resulted from an increase in reimbursement rates partially offset by change in patient mix.

Growth in revenues and discharges for the nine months ended September 30, 2023 were impacted primarily by the same factors as discussed above for the third quarter of 2023. Discharge growth included a 4.9% increase in same-store discharges. Discharge growth from new stores during the nine months ended September 30, 2023 compared to the same period of 2022 also resulted from our joint ventures in Shiloh, Illinois (February 2022) and Cape Coral, Florida (June 2022), as well as wholly owned hospitals in St. Augustine, Florida (March 2022), Libertyville, Illinois (March 2022), Lakeland, Florida (May 2022), and Jacksonville, Florida (June 2022). Growth in net patient revenue per discharge during the nine months ended September 30, 2023 compared to the same period of 2022 primarily resulted from an increase in reimbursement rates partially offset by the resumption of sequestration on April 1, 2022 and change in patient mix.

#### Salaries and Benefits

*Salaries and benefits* increased during the three and nine months ended September 30, 2023 compared to the same periods of 2022 primarily due to salary and benefit cost increases for our employees and increased patient volumes, including an increase in the number of full-time equivalents as a result of our development activities. *Salaries and benefits* decreased as a percent of *Net operating revenues* during the three and nine months ended September 30, 2023 compared to the same periods of 2022 primarily due to decreases in both contract labor and sign-on and shift bonuses ($33.3 million and $106.4 million during the three and nine months ended September 30, 2023, respectively, compared to $49.0 million and $168.9 million during the three and nine months ended September 30, 2022).

#### Other Operating Expenses

*Other operating expenses* increased in terms of dollars during the three and nine months ended September 30, 2023 compared to the same periods of 2022 primarily due to increased provider taxes and higher costs associated with property tax, maintenance contracts, insurance, and utilities resulting from our development activities. *Other operating expenses* decreased as a percent of *Net operating revenues* during the three and nine months ended September 30, 2023 compared to the same periods of 2022 primarily due to higher volumes.

#### General and Administrative Expenses

*General and administrative expenses* increased in terms of dollars and as a percent of *Net operating revenues* during the three and nine months ended September 30, 2023 compared to the same periods of 2022 primarily due to higher incentive compensation costs.

#### Depreciation and Amortization

*Depreciation and amortization* increased during the three months ended September 30, 2023 compared to the same period of 2022 due to our capital investments. *Depreciation and amortization* increased during the nine months ended September 30, 2023 compared to the same period of 2022 due to our capital investments and $6.1 million related to the accelerated amortization of the remaining carrying value of certificate of need (“CON”) assets in South Carolina. In May 2023, the governor of South Carolina signed into law S.164, which repealed the requirement of certain healthcare providers to obtain and/or maintain a CON. We expect *Depreciation and amortization* to increase going forward as a result of our recent and ongoing capital investments.

#### Interest Expense and Amortization of Debt Discounts and Fees

The decrease in *Interest expense and amortization of debt discounts and fees* during the nine months ended September 30, 2023 compared to the same period of 2022 primarily resulted from the $20.5 million consent solicitation fee paid to bond holders in June 2022 related to the Spin Off of Enhabit and the extinguishment of the term loan facilities. For additional information, see Note 5, *Long-term Debt*, to the condensed consolidated financial statements included in Part I, Item 1, *Financial Statements (Unaudited)*, of this report, and Note 10, *Long-term Debt*, to the consolidated financial statements accompanying the 2022 Form 10-K.

#### Income from Continuing Operations Before Income Tax Expense

Our pre-tax income from continuing operations increased during the three and nine months ended September 30, 2023 compared to the same periods of 2022 primarily due to the increase in *Net operating revenues* as discussed above.

#### Provision for Income Tax Expense

Our *Provision for income tax expense* increased during the three and nine months ended September 30, 2023 compared to the same periods of 2022 primarily due to higher *Income from continuing operations before income tax expense.*

We currently estimate our cash payments for income taxes to be approximately $100 million to $110 million, net of refunds, for 2023. These payments are expected to primarily result from federal and state income tax expenses based on estimates of taxable income for 2023.

In certain jurisdictions, we do not expect to generate sufficient income to use all of the available state net operating losses and other credits prior to their expiration. This determination is based on our evaluation of all available evidence in these jurisdictions including results of operations during the preceding three years, our forecast of future earnings, and prudent tax planning strategies. It is possible we may be required to increase or decrease our valuation allowance at some future time if our forecast of future earnings varies from actual results on a consolidated basis or in the applicable tax jurisdiction, if the timing of future tax deductions differs from our expectations, or pursuant to changes in state tax laws and rates.

See Note 9, *Income Taxes*, to the condensed consolidated financial statements included in Part I, Item 1, *Financial Statements (Unaudited)*, of this report and Note 16, *Income Taxes*, to the consolidated financial statements accompanying the 2022 Form 10‑K.

#### Net Income Attributable to Noncontrolling Interests

The increase in *Net income attributable to noncontrolling interests* during the three months ended September 30, 2023 compared to the same period of 2022 resulted from increased profitability from certain existing joint venture hospitals partially offset by the ramp up of new joint venture de novo locations. The increase in *Net income attributable to noncontrolling interests* during the nine months ended September 30, 2023 compared to the same period of 2022 resulted from increased profitability from certain existing joint venture hospitals partially offset by the ramp up of new joint venture de novo locations and a $2.2 million reduction to *Net income attributable to noncontrolling interests* related to the accelerated amortization of the remaining carrying value of our CON assets in South Carolina (discussed above).

### Liquidity and Capital Resources

Our primary sources of liquidity are cash on hand, cash flows from operations, and borrowings under our revolving credit facility.

The objectives of our capital structure strategy are to ensure we maintain adequate liquidity and flexibility. Pursuing and achieving those objectives allow us to support the execution of our operating and strategic plans and weather temporary disruptions in the capital markets and general business environment. Maintaining adequate liquidity is a function of our unrestricted *Cash and cash equivalents* and our available borrowing capacity. Maintaining flexibility in our capital structure is a function of, among other things, the amount of debt maturities in any given year, the options for debt prepayments without onerous penalties, and limiting restrictive terms and maintenance covenants in our debt agreements.

We have been disciplined in creating a capital structure that is flexible with no significant debt maturities prior to 2025. We continue to have a strong, well-capitalized balance sheet, including a substantial portfolio of owned real estate, and we have significant availability under our revolving credit facility. We continue to generate strong cash flows from operations and we have significant flexibility with how we choose to invest our cash and return capital to shareholders.

For additional information, see Note 5, *Long-term Debt*, to the accompanying condensed consolidated financial statements included in Part I, Item 1, *Financial Statements (Unaudited)*, of this report, and Note 10, *Long-term Debt,* to the consolidated financial statements accompanying the 2022 Form 10‑K.

#### Current Liquidity

As of September 30, 2023, we had $99.7 million in *Cash and cash equivalents.* This amount excludes $41.5 million in *Restricted cash* and $122.0 million of restricted marketable securities ($37.2 million included in *Other current assets* and $84.8 million included in *Other long-term assets* in our condensed consolidated balance sheet). Our restricted assets pertain primarily to obligations associated with our captive insurance company, as well as obligations we have under agreements with joint venture partners. See Note 5, *Cash and Marketable Securities*, to the consolidated financial statements accompanying the 2022 Form 10‑K.

In addition to *Cash and cash equivalents*, as of September 30, 2023, we had approximately $966 million available to us under our revolving credit facility. Our credit agreement governs the substantial majority of our senior secured borrowing capacity and contains a leverage ratio and an interest coverage ratio as financial covenants. Our leverage ratio is defined in our credit agreement as the ratio of consolidated total debt (less cash on hand) to Adjusted EBITDA for the trailing four quarters. In calculating the leverage ratio under our credit agreement, we are permitted to use pro forma Adjusted EBITDA, the calculation of which includes historical income statement items and pro forma adjustments, subject to certain limitations, resulting from (1) dispositions and repayments or incurrence of debt and (2) investments, acquisitions, mergers, amalgamations, consolidations and other operational changes to the extent such items or effects are not yet reflected in our trailing four-quarter financial statements. Our interest coverage ratio is defined in our credit agreement as the ratio of Adjusted EBITDA to consolidated interest expense, excluding the amortization of financing fees, for the trailing four quarters. As of September 30, 2023, the maximum leverage ratio requirement per our credit agreement was 4.75x and the minimum interest coverage ratio requirement was 3.0x, and we were in compliance with these covenants. Based on Adjusted EBITDA for the trailing four quarters and the interest rate in effect under our credit agreement during the three-month period ended September 30, 2023, if we had drawn on the first day and maintained the maximum amount of outstanding draws under our revolving credit facility for that entire period, we would still be in compliance with the maximum leverage ratio and minimum interest coverage ratio requirements.

On December 9, 2021, we announced the commencement of a consent solicitation of holders of our 5.75% Senior Notes due 2025, 4.50% Senior Notes due 2028 (the “2028 Notes”), 4.75% Senior Notes due 2030 (the “2030 Notes”), and 4.625% Senior Notes due 2031 (the “2031 Notes” and collectively the “Notes”) for the adoption of certain amendments to an indenture (the “Base Indenture”) dated as of December 1, 2009, as supplemented by each Notes’ respective supplemental indenture (together with the Base Indenture, the “Indenture”), which provided us with greater flexibility in effecting the Spin Off discussed in the “Executive Overview” section of this Item. Each Indenture contains restrictive covenants that, among other things, limit our ability and the ability of certain of our subsidiaries to make certain asset dispositions, investments, and distributions to holders of our capital stock. The amendments to the Indentures permitted us, subject to the leverage ratio condition set forth below, to distribute to our equity holders in one or more transactions (a “Distribution”) some or all of the common stock of a subsidiary that holds substantially all of the assets of our home health and hospice business. We were permitted to make any such distribution so long as the Leverage Ratio (as defined in each Indenture) was no more than 3.5 to 1.0 on a pro forma basis after giving effect thereto. The amendments also reduced the capacity under our restricted payments builder basket under each existing Indenture for the 2028 Notes, 2030 Notes, and 2031 Notes by $200 million and amended the definition of “Consolidated Net Income” to allow us to exclude from Consolidated Net Income (a component of the Leverage Ratio) any fees, expenses or charges related to any Distribution and the solicitation of consents from the holders of the Notes. In December 2021 and January 2022, we received the requisite consents for the adoption of these amendments. Under the terms of the amendments, we agreed to pay the holders of the Notes a total of $40.5 million, excluding fees. We paid $20.0 million and $20.5 million in January and June 2022, respectively.

We do not face near-term refinancing risk, as the amounts outstanding under our credit agreement do not mature until 2027, and our bonds all mature in 2025 and beyond. See the “Contractual Obligations” section below for information related to our contractual obligations as of September 30, 2023.

For a discussion of risks and uncertainties facing us see Item 1A, *Risk Factors,* under Part II, *Other Information*, of this report and Item 1A, *Risk Factors*, of the 2022 Form 10‑K.

#### Sources and Uses of Cash

The following table shows the cash flows provided by or used in operating, investing, and financing activities of continuing operations (in millions):

|  | Nine Months Ended September 30, 2023 | 2022 |
| --- | ---: | ---: |
| Net cash provided by operating activities | $654.4 | $477.6 |
| Net cash used in investing activities | (394.7) | (417.0) |
| Net cash used in financing activities | (167.3) | (645.3) |
| Increase (decrease) in cash, cash equivalents, and restricted cash | $92.4 | $(584.7) |

*Operating activities*. The increase in *Net cash provided by operating activities* of continuing operations for the nine months ended September 30, 2023 compared to the same period of 2022 primarily resulted from an increase in *Net income* which was driven by growth in *Net operating revenues.*

*Investing activities*. The decrease in *Net cash used in investing activities* of continuing operations during the nine months ended September 30, 2023 compared to the same period of 2022 primarily resulted from decreased purchases of property and equipment.

*Financing activities*. The decrease in *Net cash used in financing activities* of continuing operations during the nine months ended September 30, 2023 compared to the same period of 2022 primarily resulted from lower net debt payments, debt amendment costs, and dividends paid on commons stock. For additional information on debt payments, see Note 5, *Long-term Debt*, to the accompanying condensed consolidated financial statements included in Part I, Item 1, *Financial Statements (Unaudited)*, of this report.

#### Contractual Obligations

Our consolidated contractual obligations as of September 30, 2023 are as follows (in millions):

| Long-term debt obligations: | Total | Current | Long-term |
| --- | ---: | ---: | ---: |
| Long-term debt, excluding revolving credit facility and finance lease obligations (a) | $2,371.3 | $2.8 | $2,368.5 |
| Interest on long-term debt (b) | 587.6 | 117.6 | 470.0 |
| Finance lease obligations (c) | 516.6 | 46.2 | 470.4 |
| Operating lease obligations (d) | 277.9 | 36.9 | 241.0 |
| Purchase obligations (e) | 149.1 | 36.9 | 112.2 |
| Total | $3,902.5 | $240.4 | $3,662.1 |

(a) Included in long-term debt are amounts owed on our bonds payable and other notes payable. These borrowings are further explained in Note 5, *Long-term Debt*, accompanying the condensed consolidated financial statements included in Part I, Item 1, *Financial Statements (Unaudited)*, of this report, and Note 10, *Long-term Debt,* to the consolidated financial statements accompanying the 2022 Form 10‑K.

(b) Interest on our fixed rate debt is presented using the stated interest rate. Interest pertaining to our credit agreement and bonds is included to their respective ultimate maturity dates. Interest related to finance lease obligations is excluded from this line. Amounts exclude amortization of debt discounts, amortization of loan fees, or fees for lines of credit that would be included in interest expense in our condensed consolidated statements of comprehensive income.

(c) Amounts include interest portion of future minimum finance lease payments.

(d) We lease approximately 9% of our hospitals as well as other property and equipment under operating leases in the normal course of business. Amounts include interest portion of future minimum operating lease payments. For more information, see Note 8, *Leases,* to the consolidated financial statements accompanying the 2022 Form 10‑K.

(e) Purchase obligations include agreements to purchase goods or services that are enforceable and legally binding on Encompass Health and that specify all significant terms, including: fixed or minimum quantities to be purchased; fixed, minimum, or variable price provisions; and the approximate timing of the transaction. Purchase obligations exclude agreements that are cancelable without penalty. Our purchase obligations primarily relate to software licensing and support and medical equipment. Purchase obligations are not recognized in our condensed consolidated balance sheet.

Our capital expenditures include costs associated with our hospital renovation program, de novo projects, capacity expansions, technology initiatives, and building and equipment upgrades and purchases. During the nine months ended September 30, 2023, we made capital expenditures of approximately $371 million for property and equipment, capitalized software, and other intangible assets. During 2023, we expect to spend approximately $590 million to $620 million for capital expenditures using cash on hand and borrowings under our revolving credit facility. Approximately $210 million to $220 million of this budgeted amount is considered nondiscretionary expenditures, which we may refer to in other filings as “maintenance” expenditures. Actual amounts spent will be dependent upon the timing of development projects.

#### Authorizations for Returning Capital to Stakeholders

In October 2022, February 2023, May 2023, and July 2023, our board of directors declared cash dividends of $0.15 per share that were paid in January 2023, April 2023, July 2023, and October 2023, respectively. On October 19, 2023, our board of directors declared a cash dividend of $0.15 per share, payable on January 16, 2024 to stockholders of record on January 2, 2024. We expect quarterly dividends to be paid in January, April, July, and October. However, the actual declaration of any future cash dividends, and the setting of record and payment dates as well as the per share amounts, will be at the discretion of our board of directors after consideration of various factors, including our capital position and alternative uses of funds. Cash dividends are expected to be funded using cash flows from operations, cash on hand, and availability under our revolving credit facility.

The terms of our credit agreement allow us to declare and pay cash dividends on our common stock so long as: (1) we are not in default under our credit agreement, and (2) either (a) our senior secured leverage ratio (as defined in our credit agreement) remains less than or equal to 2x and our leverage ratio (as defined in our credit agreement) remains less than or equal to 4.50x or (b) our leverage ratio remains in compliance with the leverage ratio covenant and there is capacity under the Available Amount as defined in the credit agreement. The terms of our Notes indenture allow us to declare and pay cash dividends on our common stock so long as (1) we are not in default, (2) the consolidated coverage ratio (as defined in the indenture) exceeds 2x or we are otherwise allowed under the indenture to incur debt, and (3) we have capacity under the indenture’s restricted payments covenant to declare and pay dividends. See Note 5, *Long-term Debt*, to the accompanying condensed consolidated financial statements included in Part I, Item 1, *Financial Statements (Unaudited)*, of this report, and Note 10, *Long-term Debt*, to the consolidated financial statements accompanying the 2022 Form 10‑K.

On July 24, 2018, our board approved resetting the aggregate common stock repurchase authorization to $250 million. As of September 30, 2023, approximately $198 million remained under this authorization. The repurchase authorization does not require the repurchase of a specific number of shares, has an indefinite term, and is subject to termination at any time by our board of directors. Subject to certain terms and conditions, including a maximum price per share and compliance with federal and state securities and other laws, the repurchases may be made from time to time in open market transactions, privately negotiated transactions, or other transactions, including trades under a plan established in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. For additional information, see Part II, Item 2, *Unregistered Sales of Equity Securities and Use of Proceeds,* of this report.

#### Supplemental Guarantor Financial Information

Our indebtedness under our credit agreement and the Notes are guaranteed by certain consolidated subsidiaries. These guarantees are full and unconditional and joint and several, subject to certain customary conditions for release. The Notes are guaranteed on a senior, unsecured basis by all of our existing and future subsidiaries that guarantee borrowings under our credit agreement and other capital markets debt. The other subsidiaries of Encompass Health do not guarantee the Notes (such subsidiaries are referred to as the “non-guarantor subsidiaries”).

Summarized financial information is presented below for Encompass Health, the parent company, and the subsidiary guarantors on a combined basis after elimination of intercompany transactions and balances among Encompass Health and the subsidiary guarantors and does not include investments in and equity in the earnings of non-guarantor subsidiaries.

*(In Millions)*

|  | Nine Months Ended September 30, 2023 |
| --- | ---: |
| Net operating revenues | $2,252.6 |
| Intercompany revenues generated from non-guarantor subsidiaries | 67.5 |
| Total net operating revenues | $2,320.1 |
| Operating expenses | $1,970.7 |
| Intercompany expenses incurred in transactions with non-guarantor subsidiaries | 25.2 |
| Total operating expenses | $1,995.9 |
| Income from continuing operations | $162.9 |
| Net income | $159.4 |
| Net income attributable to Encompass Health | $159.4 |

*(In Millions)*

|  | As of September 30, 2023 | As of December 31, 2022 |
| --- | ---: | ---: |
| Total current assets | $517.5 | $466.3 |
| Property and equipment, net | $2,147.6 | $1,975.0 |
| Goodwill | 902.6 | 902.6 |
| Intercompany receivable due from non-guarantor subsidiaries | 217.2 | 254.9 |
| Other noncurrent assets | 463.3 | 508.2 |
| Total noncurrent assets | $3,730.7 | $3,640.7 |
| Total current liabilities | $479.0 | $437.8 |
| Long-term debt, net of current portion | $2,607.6 | $2,670.6 |
| Other noncurrent liabilities | 322.7 | 349.7 |
| Total noncurrent liabilities | $2,930.3 | $3,020.3 |

#### Adjusted EBITDA

Management believes Adjusted EBITDA as defined in our credit agreement is a measure of our ability to service our debt and our ability to make capital expenditures. We reconcile Adjusted EBITDA to *Net cash provided by operating activities* and to *Net income.*

We use Adjusted EBITDA on a consolidated basis as a liquidity measure. We believe this financial measure on a consolidated basis is important in analyzing our liquidity because it is the key component of certain material covenants contained within our credit agreement, which is discussed in more detail in Note 10, *Long-term Debt*, to the consolidated financial statements accompanying the 2022 Form 10‑K. These covenants are material terms of the credit agreement. Noncompliance with these financial covenants under our credit agreement—our interest coverage ratio and our leverage ratio—could result in our lenders requiring us to immediately repay all amounts borrowed. If we anticipated a potential covenant violation, we would seek relief from our lenders, which would have some cost to us, and such relief might be on terms less favorable to us than those in our existing credit agreement. In addition, if we cannot satisfy these financial covenants, we would be prohibited under our credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying common stock dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA is critical to our assessment of our liquidity.

In general terms, the credit agreement definition of Adjusted EBITDA, therein referred to as “Adjusted Consolidated EBITDA,” allows us to add back to consolidated *Net income* interest expense, income taxes, and depreciation and amortization and then add back to consolidated *Net income* (1) all unusual or nonrecurring items reducing consolidated *Net income* (of which only up to $10 million in a year may be cash expenditures), (2) any losses from discontinued operations, (3) non-ordinary course fees, costs and expenses incurred with respect to any litigation or settlement, (4) share-based compensation expense, (5) costs and expenses associated with changes in the fair value of marketable securities, (6) costs and expenses associated with the issuance or prepayment of debt, and acquisitions, and (7) any restructuring charges and certain pro forma cost savings and synergies related to transactions and initiatives, which in the aggregate are not in excess of 25% of Adjusted Consolidated EBITDA. We also subtract from consolidated *Net income* all unusual or nonrecurring items to the extent they increase consolidated *Net income.*

Under the credit agreement, the Adjusted EBITDA calculation does not require us to deduct net income attributable to noncontrolling interests or gains on fair value adjustments of hedging and equity instruments, disposal of assets, and development activities. It also does not allow us to add back losses on fair value adjustments of hedging instruments or unusual or nonrecurring cash expenditures in excess of $10 million. These items and amounts, in addition to the items falling within the credit agreement’s “unusual or nonrecurring” classification, may occur in future periods, but can vary significantly from period to period and may not directly relate to, or be indicative of, our ongoing liquidity or operating performance. Accordingly, the Adjusted EBITDA calculation presented here includes adjustments for them.

Adjusted EBITDA is not a measure of financial performance under generally accepted accounting principles in the United States of America, and the items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Therefore, Adjusted EBITDA should not be considered a substitute for *Net income* or cash flows from operating, investing, or financing activities. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Revenues and expenses are measured in accordance with the policies and procedures described in Note 1, *Summary of Significant Accounting Policies*, to the consolidated financial statements accompanying the 2022 Form 10‑K.

Our Adjusted EBITDA was as follows (in millions):

### Reconciliation of Net Cash Provided by Operating Activities to Adjusted EBITDA

|  | Nine Months Ended September 30, 2023 | 2022 |
| --- | ---: | ---: |
| **Net cash provided by operating activities** | $649.8 | $533.6 |
| Interest expense and amortization of debt discounts and fees | 108.6 | 138.2 |
| Loss on sale of investments, excluding impairments | (0.9) | (16.5) |
| Equity in net income of nonconsolidated affiliates | 2.3 | 2.6 |
| Net income attributable to noncontrolling interests in continuing operations | (79.5) | (65.5) |
| Amortization of debt-related items | (7.1) | (7.4) |
| Distributions from nonconsolidated affiliates | (0.6) | (3.7) |
| Current portion of income tax expense | 97.9 | 75.9 |
| Change in assets and liabilities | (58.9) | (23.5) |
| Cash used in (provided by) operating activities of discontinued operations | 4.6 | (56.0) |
| State regulatory change impact on noncontrolling interests | (2.2) | — |
| Change in fair market value of equity securities | 2.1 | 8.8 |
| Other | — | 0.1 |
| **Adjusted EBITDA** | $716.1 | $586.6 |

31

### Reconciliation of Net Income to Adjusted EBITDA

|  | Three Months Ended September 30, 2023 | 2022 | Nine Months Ended September 30, 2023 | 2022 |
| --- | ---: | ---: | ---: | ---: |
| **Net income** | $113.4 | $67.0 | $343.9 | $248.4 |
| Loss (income) from discontinued operations, net of tax, attributable to Encompass Health | 1.3 | 18.5 | 3.5 | (16.7) |
| Net income attributable to noncontrolling interests included in continuing operations | (28.1) | (21.6) | (79.5) | (65.5) |
| Provision for income tax expense | 30.3 | 21.8 | 95.0 | 68.2 |
| Interest expense and amortization of debt discounts and fees | 35.9 | 38.2 | 108.6 | 138.2 |
| Loss (gain) on disposal or impairment of assets | 2.2 | (1.1) | 3.7 | 2.4 |
| Depreciation and amortization | 67.3 | 62.1 | 203.8 | 180.3 |
| Loss on early extinguishment of debt | — | — | — | 1.4 |
| Stock-based compensation | 13.7 | 7.3 | 37.2 | 21.1 |
| State regulatory change impact on noncontrolling interests | — | — | (2.2) | — |
| Change in fair market value of equity securities | 1.5 | 3.1 | 2.1 | 8.8 |
| **Adjusted EBITDA** | $237.5 | $195.3 | $716.1 | $586.6 |

For additional information see the “Results of Operations” section of this Item.

### Recent Accounting Pronouncements

For information regarding recent accounting pronouncements, see Note 1, *Basis of Presentation*, to our condensed consolidated financial statements included under Part I, Item 1, *Financial Statements (Unaudited)*, of this report.

## Controls and procedures

As filed, 835 characters.

### Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, an evaluation was carried out by our management, including our chief executive officer and chief financial officer, of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended. Based on our evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this report.

### Changes in Internal Control Over Financial Reporting

There have been no changes in our Internal Control over Financial Reporting during the quarter ended September 30, 2023 that have a material effect on our Internal Control over Financial Reporting.

## Risk factors

As filed, 438 characters.

There have been no material changes from the risk factors disclosed in Part I, Item 1A, *Risk Factors*, of the 2022 Form 10-K. However, certain information in those risk factors has been updated by the discussion in the “Executive Overview—Key Challenges” section of Part I, Item 2, *Management’s Discussion and Analysis of Financial Condition and Results of Operations*, of this report, which section is incorporated by reference herein.

Filed Nov 1, 2023.
Source: SEC EDGAR, the filing index for accession 0000785161-23-000070. Last ingested by Listed: Nov 6, 2026, 12:04 ET. No prices; not investment advice.
